Approximately 20% of compounds in the currently ongoingclinicaltrials for AD target Aβ and tau proteins.5 In Aβ/tau-oriented projects, the focus is placedon reducing Aβ/tau formation and aggregation or inducing theremoval of already formed deposits of proteins.6 Such effects can be obtained by using protein aggregationinhibitors, antibodies, and enzyme inhibitors. The gene discussed is MAPT; the disease is Alzheimer disease.